Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−9.1804USD
−26.48 MUSD
4.76 MUSD
9.17 M
About DMK Pharmaceuticals Corporation
Sector
CEO
Ebrahim Versi
Headquarters
San Diego
Website
Employees (FY)
11
Founded
2006
FIGI
BBG000BYBPQ6
DMK Pharmaceuticals Corp. is a biopharmaceutical company, which engages in the discovery, development, and sale of pharmaceutical, specialty biopharmaceutical, and other drug products. The company provides products in various therapeutic areas, including allergy, respiratory, opioid overdose, and erectile dysfunction markets. It offers the SYMJEPI Injection for the emergency treatment of allergic reactions. The company was founded in June 2006 and is headquartered in San Diego, CA.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of DMKPQ is 0.0500 USD — it has increased by 50.15% in the past 24 hours. Watch DMK Pharmaceuticals Corporation stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on OTC exchange DMK Pharmaceuticals Corporation stocks are traded under the ticker DMKPQ.
DMK Pharmaceuticals Corporation is going to release the next earnings report on May 13, 2024. Keep track of upcoming events with our Earnings Calendar.
DMKPQ stock is 80.18% volatile and has beta coefficient of 0.38. Track DMK Pharmaceuticals Corporation stock price on the chart and check out the list of the most volatile stocks — is DMK Pharmaceuticals Corporation there?
Yes, you can track DMK Pharmaceuticals Corporation financials in yearly and quarterly reports right on TradingView.
DMKPQ stock has risen by 20.19% compared to the previous week, the month change is a 3.85% fall, over the last year DMK Pharmaceuticals Corporation has showed a 99.11% decrease.
DMKPQ net income for the last quarter is −1.39 M USD, while the quarter before that showed −8.57 M USD of net income which accounts for 83.81% change. Track more DMK Pharmaceuticals Corporation financial stats to get the full picture.
Today DMK Pharmaceuticals Corporation has the market capitalization of 505.10 K, it has decreased by 16.00% over the last week.
No, DMKPQ doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, DMKPQ shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade DMK Pharmaceuticals Corporation stock right from TradingView charts — choose your broker and connect to your account.
DMKPQ reached its all-time high on May 10, 2016 with the price of 767.8325 USD, and its all-time low was 0.0331 USD and was reached on Feb 14, 2024. View more price dynamics on DMKPQ chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
As of May 6, 2024, the company has 11.00 employees. See our rating of the largest employees — is DMK Pharmaceuticals Corporation on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So DMK Pharmaceuticals Corporation technincal analysis shows the neutral today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating DMK Pharmaceuticals Corporation stock shows the sell signal. See more of DMK Pharmaceuticals Corporation technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. DMK Pharmaceuticals Corporation EBITDA is −18.25 M USD, and current EBITDA margin is −496.05%. See more stats in DMK Pharmaceuticals Corporation financial statements.